Treatment Experience and Predictive Factors Associated with Response in Platinum-Resistant Recurrent Ovarian Cancer: A Retrospective Single-Institution Study
| Autor: | Roxana Margan, Valeria Mocanu, Dorel Popovici, Sorin Săftescu, Șerban Negru, Adelina Silvana Dragomir, Radu Dragomir, Ioan Sas, Cristina Pac, Horia Tudor Stanca |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy predictive factors Bevacizumab Serous carcinoma business.industry allergology Mortality rate Incidence (epidemiology) medicine.medical_treatment Renal function General Medicine medicine.disease platinum resistance Article ovarian cancer Internal medicine medicine Medicine Topotecan business Ovarian cancer medicine.drug |
| Zdroj: | Journal of Clinical Medicine Journal of Clinical Medicine, Vol 10, Iss 3596, p 3596 (2021) Volume 10 Issue 16 |
| DOI: | 10.20944/preprints202105.0391.v1 |
| Popis: | Ovarian cancer (OC) represents the most common and lethal gynecologic malignancy, due to its increased incidence and mortality rate. It is usually diagnosed in advanced stages and, even though surgery and platinum-based treatments are initially efficient, recurrences emerge in over 70% of cases. Although there are multiple options of chemotherapy drugs from which to choose, little is known regarding the best strategy for prolonged survival. Thus, this study aimed to assess the effect that most frequently used chemotherapeutic regimens have upon time-to-treatment-failure (TTF) from the first line and beyond, considering clinical and biological factors which influence the treatment outcome of platinum-resistant recurrent OC. We retrospectively analyzed data from 78 patients diagnosed with platinum-resistant OC, who underwent chemotherapy-based treatment with or without anti-angiogenic therapy at OncoHelp Oncology Center, Romania (January 2016–February 2021). Our study identified positive predictive factors for TTF related to histology (serous carcinoma subtype), anthropometry (age over 60 for patients treated with topotecan with or without bevacizumab), renal function (creatinine levels between 0.65 and 1 mg/dL for patients treated with regimens containing bevacizumab and pegylated liposomal doxorubicin) and treatment choice (bevacizumab in combination with pegylated liposomal doxorubicin or topotecan used from the first line and beyond). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|